Get the Stockscreener App
1.67
11.33%
0.17
After Hours:
1.65
-0.02
-1.20%
Ocugen Inc stock is traded at $1.67, with a volume of 14.14M.
It is up +11.33% in the last 24 hours and up +21.01% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.50
Open:
$1.53
24h Volume:
14.14M
Relative Volume:
1.82
Market Cap:
$565.33M
Revenue:
$4.47M
Net Income/Loss:
$-71.67M
P/E Ratio:
-7.2045
EPS:
-0.2318
Net Cash Flow:
$-59.58M
1W Performance:
+29.46%
1M Performance:
+21.01%
6M Performance:
+12.84%
1Y Performance:
+69.70%
1-Day Range:
$1.51
$1.68
1-Week Range:
$1.28
$1.68
52-Week Range:
$0.9029
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.67 | 507.78M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Index - marketscreener.com
OCGN Stock Grinds Higher As Traders Track Tight Range - StocksToTrade
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Value Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 3000E Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Index - marketscreener.com
Why Did OCGN Stock Rise Today? - Stocktwits
OCGN Stock Holds Buy Rating As Analyst Sees Key Catalysts Ahead - StocksToTrade
Enterprise value to EBITDA forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI
Price to book forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Ocugen Inc Actuals & Estimates (NASDAQ:OCGN) - TradingView
Price to book forward of Ocugen Inc – SWB:2H51 - TradingView
Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enterprise value to revenue forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Ocugen's gene-agnostic eye therapies could reshape late-stage care - MSN
Price to earnings forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Price to sales forward of Ocugen Inc – SWB:2H51 - TradingView
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Price to earnings forward of Ocugen Inc – SWB:2H51 - TradingView
OCGN Forecast — Price Target — Prediction for 2027 - TradingView
Ocugen (OCGN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Ocugen: Financing Risk Is Lower, But The Clinical Bet Still Has To Work - Seeking Alpha
Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View - Yahoo Finance
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
OCGN Stock Holds Buy Rating As Analyst Trims Price Target - StocksToTrade
Ocugen completes OCU400 Phase 3 enrollment, shares trade in tight NASDAQ range - Ad-hoc-news.de
Ocugen StockFriday review and biotech sector context - AD HOC NEWS
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc (OCGN) Institutional Confidence - TradingKey
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ocugen Inc (OCGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ocugen Inc (OCGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocugen Inc (OCGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen (NASDAQ: OCGN) director receives grant of 170,100 stock options at $1.22 - Stock Titan
Ocugen, Inc.'s (NASDAQ:OCGN) Profit Outlook - Moomoo
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen (NASDAQ: OCGN) shareholders back pay, elect directors and confirm new CMO - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
OCGN: All agenda items, including director elections and compensation votes, were approved - TradingView
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc stock (US67577C1053): pipeline updates keep biotech investors watching - AD HOC NEWS
Ocugen Inc stock (US67577C1053): Short interest jumps as investors weigh biotech pipeline - AD HOC NEWS
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):